Num |
microRNA |
Gene |
miRNA log2FC |
miRNA pvalue |
Gene log2FC |
Gene pvalue |
Interaction |
Correlation beta |
Correlation P-value |
PMID |
Reported in cancer studies |
1 |
hsa-miR-145-5p |
ABCE1 |
-0.54 |
0.27552 |
0.22 |
0.3851 |
MirTarget |
-0.11 |
0 |
|
NA |
2 |
hsa-miR-145-5p |
ACVR1B |
-0.54 |
0.27552 |
0.49 |
0.03728 |
MirTarget; miRNATAP |
-0.11 |
0 |
|
NA |
3 |
hsa-miR-145-5p |
ADI1 |
-0.54 |
0.27552 |
0 |
0.99386 |
MirTarget |
-0.12 |
0 |
|
NA |
4 |
hsa-miR-145-5p |
ADM2 |
-0.54 |
0.27552 |
0.18 |
0.37664 |
mirMAP |
-0.38 |
0 |
|
NA |
5 |
hsa-miR-145-5p |
AIFM1 |
-0.54 |
0.27552 |
0.14 |
0.58326 |
miRNATAP |
-0.17 |
0 |
20332243 |
Artificial overexpression of miR145 by using adenoviral vectors in prostate cancer PC-3 and DU145 cells significantly downregulated BNIP3 together with the upregulation of AIF reduced cell growth and increased cell death |
6 |
hsa-miR-145-5p |
AKIRIN1 |
-0.54 |
0.27552 |
0.54 |
0.02828 |
miRNATAP |
-0.13 |
0 |
|
NA |
7 |
hsa-miR-145-5p |
AKR1B10 |
-0.54 |
0.27552 |
-0.04 |
0.91097 |
miRNAWalker2 validate |
-0.31 |
0.00423 |
|
NA |
8 |
hsa-miR-145-5p |
APH1A |
-0.54 |
0.27552 |
0.3 |
0.3297 |
miRNAWalker2 validate |
-0.15 |
0 |
|
NA |
9 |
hsa-miR-145-5p |
ARPC5 |
-0.54 |
0.27552 |
0.14 |
0.63233 |
MirTarget |
-0.1 |
0 |
|
NA |
10 |
hsa-miR-145-5p |
BNIP3 |
-0.54 |
0.27552 |
-0.26 |
0.30088 |
miRNAWalker2 validate; miRTarBase |
-0.23 |
0 |
20332243 |
Artificial overexpression of miR145 by using adenoviral vectors in prostate cancer PC-3 and DU145 cells significantly downregulated BNIP3 together with the upregulation of AIF reduced cell growth and increased cell death; Analysis of prostate cancer n = 134 and benign prostate n = 83 tissue sample showed significantly decreased miR145 and increased BNIP3 expression in prostate cancer P < 0.001 particularly in those with tumor progression and both molecular changes were associated with unfavorable outcome |
11 |
hsa-miR-145-5p |
C1QL4 |
-0.54 |
0.27552 |
1.17 |
0.00011 |
miRNATAP |
-0.35 |
4.0E-5 |
|
NA |
12 |
hsa-miR-145-5p |
CD47 |
-0.54 |
0.27552 |
1.25 |
2.0E-5 |
miRNATAP |
-0.14 |
3.0E-5 |
|
NA |
13 |
hsa-miR-145-5p |
CDR2L |
-0.54 |
0.27552 |
1 |
5.0E-5 |
MirTarget; miRNATAP |
-0.11 |
0.00054 |
|
NA |
14 |
hsa-miR-145-5p |
CHAC2 |
-0.54 |
0.27552 |
0.22 |
0.07982 |
MirTarget |
-0.27 |
0 |
|
NA |
15 |
hsa-miR-145-5p |
CLDN9 |
-0.54 |
0.27552 |
2.66 |
0 |
MirTarget |
-0.43 |
0 |
|
NA |
16 |
hsa-miR-145-5p |
COMMD5 |
-0.54 |
0.27552 |
-0.04 |
0.84128 |
MirTarget |
-0.12 |
0 |
|
NA |
17 |
hsa-miR-145-5p |
COX16 |
-0.54 |
0.27552 |
-0.1 |
0.67243 |
MirTarget |
-0.11 |
0 |
|
NA |
18 |
hsa-miR-145-5p |
CSTF3 |
-0.54 |
0.27552 |
-0.01 |
0.96564 |
MirTarget |
-0.13 |
0 |
|
NA |
19 |
hsa-miR-145-5p |
DLX6 |
-0.54 |
0.27552 |
-1.09 |
0.0001 |
miRNATAP |
-0.21 |
0.0075 |
|
NA |
20 |
hsa-miR-145-5p |
DNAJB11 |
-0.54 |
0.27552 |
0.52 |
0.04245 |
miRNATAP |
-0.21 |
0 |
|
NA |
21 |
hsa-miR-145-5p |
DNMT3B |
-0.54 |
0.27552 |
0.76 |
0 |
MirTarget |
-0.31 |
0 |
24071015; 25749421 |
In univariate analysis the combination of DNMT3B overexpression and miR-145 or miR-143 down-regulation was more powerful in predicting shorter survival P < .05 than use of the biomarkers individually P > .05; DNMT3B might be a potential target of miR-145 and miR-143 in ECs; Furthermore the combined miR-145 or miR-143 and DNMT3B status may have a prognostic impact on ECs;It was found that miR-145 upregulates while DNMT3b downregulates in PC3 cells; Responses of the miR-145 and DNMT3b to irradiation are a negative correlation; We also found that either overexpression of miR-145 or knockdown of DNMT3b sensitized prostate cancer cells to X-ray radiation |
22 |
hsa-miR-145-5p |
DTD1 |
-0.54 |
0.27552 |
0.23 |
0.26537 |
miRNAWalker2 validate |
-0.1 |
0 |
|
NA |
23 |
hsa-miR-145-5p |
E2F3 |
-0.54 |
0.27552 |
0.51 |
0.00503 |
miRNATAP |
-0.2 |
0 |
25762621 |
miR 145 mediates the antiproliferative and gene regulatory effects of vitamin D3 by directly targeting E2F3 in gastric cancer cells; Furthermore miR-145 expression was lower in tumors compared with matched normal samples and correlated with increased the E2F3 transcription factor protein staining |
24 |
hsa-miR-145-5p |
EFNA3 |
-0.54 |
0.27552 |
0.3 |
0.0717 |
miRNATAP |
-0.25 |
0 |
|
NA |
25 |
hsa-miR-145-5p |
ELFN2 |
-0.54 |
0.27552 |
2.05 |
0 |
mirMAP |
-0.25 |
0.00269 |
|
NA |
26 |
hsa-miR-145-5p |
ELK4 |
-0.54 |
0.27552 |
0.1 |
0.4221 |
miRNATAP |
-0.12 |
0 |
|
NA |
27 |
hsa-miR-145-5p |
ENC1 |
-0.54 |
0.27552 |
-0.36 |
0.15809 |
MirTarget |
-0.15 |
0.00034 |
|
NA |
28 |
hsa-miR-145-5p |
ESCO2 |
-0.54 |
0.27552 |
-0.22 |
0.21296 |
MirTarget |
-0.46 |
0 |
|
NA |
29 |
hsa-miR-145-5p |
F11R |
-0.54 |
0.27552 |
-0.13 |
0.66813 |
miRNAWalker2 validate |
-0.18 |
0 |
20818426; 26374689 |
Our data identify JAM-A and fascin as novel targets of miR-145 firmly establishing a role for miR-145 in modulating breast cancer cell motility;MicroRNA screening predicted that microRNA-145 miR-145 would bind to JAM-A; Using patient-derived glioblastoma CSCs we confirmed that JAM-A is suppressed by miR-145 |
30 |
hsa-miR-145-5p |
FAM110C |
-0.54 |
0.27552 |
-0.29 |
0.18407 |
MirTarget |
-0.12 |
0.04892 |
|
NA |
31 |
hsa-miR-145-5p |
FAM49B |
-0.54 |
0.27552 |
0.71 |
0.00116 |
MirTarget |
-0.25 |
0 |
|
NA |
32 |
hsa-miR-145-5p |
FOXD4 |
-0.54 |
0.27552 |
-0.19 |
0.20451 |
MirTarget |
-0.13 |
0.00138 |
|
NA |
33 |
hsa-miR-145-5p |
FOXD4L1 |
-0.54 |
0.27552 |
-0.09 |
0.53984 |
MirTarget |
-0.12 |
0.00306 |
|
NA |
34 |
hsa-miR-145-5p |
GATC |
-0.54 |
0.27552 |
0.03 |
0.82617 |
MirTarget |
-0.1 |
0.00218 |
|
NA |
35 |
hsa-miR-145-5p |
GGT7 |
-0.54 |
0.27552 |
0.48 |
0.0266 |
MirTarget; miRNATAP |
-0.11 |
0.00059 |
|
NA |
36 |
hsa-miR-145-5p |
GMFB |
-0.54 |
0.27552 |
0.25 |
0.28294 |
miRNAWalker2 validate |
-0.12 |
0 |
|
NA |
37 |
hsa-miR-145-5p |
GTPBP8 |
-0.54 |
0.27552 |
0.4 |
0.00473 |
MirTarget |
-0.13 |
0 |
|
NA |
38 |
hsa-miR-145-5p |
H2AFX |
-0.54 |
0.27552 |
0 |
0.99213 |
MirTarget; miRNATAP |
-0.17 |
0 |
|
NA |
39 |
hsa-miR-145-5p |
HDAC2 |
-0.54 |
0.27552 |
0.25 |
0.38192 |
miRNAWalker2 validate |
-0.13 |
0 |
23499894 |
MiR 145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer; Ectopic expression of miRNA mimics evidenced that miR-145 suppresses HDAC2 expression in HCC cells; In conclusion we suggest that loss or suppression of miR-145 may cause aberrant overexpression of HDAC2 and promote HCC tumorigenesis |
40 |
hsa-miR-145-5p |
HLTF |
-0.54 |
0.27552 |
0.36 |
0.13416 |
miRNAWalker2 validate |
-0.13 |
1.0E-5 |
25666710 |
We show that miR-145 targets the DNA damage repair-associated gene Helicase-like transcription factor HLTF which is involved in radio-resistance |
41 |
hsa-miR-145-5p |
HN1L |
-0.54 |
0.27552 |
-0.33 |
0.26313 |
mirMAP |
-0.12 |
0 |
|
NA |
42 |
hsa-miR-145-5p |
ITGB8 |
-0.54 |
0.27552 |
0.99 |
0.00034 |
miRNAWalker2 validate; miRTarBase; MirTarget |
-0.16 |
0.00015 |
|
NA |
43 |
hsa-miR-145-5p |
IVNS1ABP |
-0.54 |
0.27552 |
-0.05 |
0.85528 |
MirTarget; miRNATAP |
-0.13 |
0 |
|
NA |
44 |
hsa-miR-145-5p |
KLF5 |
-0.54 |
0.27552 |
0.31 |
0.23403 |
miRTarBase; miRNATAP |
-0.11 |
0.00707 |
|
NA |
45 |
hsa-miR-145-5p |
KRT7 |
-0.54 |
0.27552 |
1.94 |
0 |
miRNAWalker2 validate |
-0.37 |
1.0E-5 |
|
NA |
46 |
hsa-miR-145-5p |
KSR2 |
-0.54 |
0.27552 |
0.61 |
0.00098 |
mirMAP |
-0.21 |
3.0E-5 |
|
NA |
47 |
hsa-miR-145-5p |
LLPH |
-0.54 |
0.27552 |
0.13 |
0.51775 |
MirTarget |
-0.11 |
0 |
|
NA |
48 |
hsa-miR-145-5p |
LRRC8B |
-0.54 |
0.27552 |
-0 |
0.98221 |
miRNATAP |
-0.14 |
0 |
|
NA |
49 |
hsa-miR-145-5p |
LYPLA2 |
-0.54 |
0.27552 |
0.15 |
0.56458 |
miRNAWalker2 validate |
-0.13 |
0 |
|
NA |
50 |
hsa-miR-145-5p |
MAGOHB |
-0.54 |
0.27552 |
0.12 |
0.48811 |
MirTarget |
-0.13 |
0 |
|
NA |
51 |
hsa-miR-145-5p |
MAP2K6 |
-0.54 |
0.27552 |
-1.2 |
0 |
miRNAWalker2 validate |
-0.15 |
0.00341 |
|
NA |
52 |
hsa-miR-145-5p |
MEST |
-0.54 |
0.27552 |
0.66 |
0.01213 |
miRNAWalker2 validate; MirTarget; miRNATAP |
-0.27 |
0 |
|
NA |
53 |
hsa-miR-145-5p |
MGAT4A |
-0.54 |
0.27552 |
1.19 |
0 |
mirMAP |
-0.19 |
0 |
|
NA |
54 |
hsa-miR-145-5p |
MMP1 |
-0.54 |
0.27552 |
0.84 |
0.00436 |
miRNAWalker2 validate |
-0.42 |
0 |
|
NA |
55 |
hsa-miR-145-5p |
MMP12 |
-0.54 |
0.27552 |
-0.01 |
0.98481 |
miRNAWalker2 validate |
-0.48 |
0 |
|
NA |
56 |
hsa-miR-145-5p |
MUC1 |
-0.54 |
0.27552 |
0.4 |
0.26653 |
miRNAWalker2 validate; miRTarBase |
-0.23 |
0.00016 |
24157791 |
MiR 145 is downregulated in human ovarian cancer and modulates cell growth and invasion by targeting p70S6K1 and MUC1; MiR-145 is found to negatively regulate P70S6K1 and MUC1 protein levels by directly targeting their 3'UTRs; Importantly the overexpression of p70S6K1 and MUC1 can restore the cell colony formation and invasion abilities that are reduced by miR-145 respectively; Our study suggests that miR-145 modulates ovarian cancer growth and invasion by suppressing p70S6K1 and MUC1 functioning as a tumor suppressor |
57 |
hsa-miR-145-5p |
MYO6 |
-0.54 |
0.27552 |
-0.03 |
0.89909 |
miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP |
-0.13 |
1.0E-5 |
20353999 |
A computational search indicated the 3'-untranslated region UTR of the mRNA for myosin VI MYO6 as a potential target for both miR-143 and miR-145 the expression of which was reduced in the tumor tissues; In luciferase reporter analysis we find a significant negative regulatory effect on the MYO6 3'UTR by both miR-143 and miR-145; Mutation of the potential binding sites for miR-143 and miR-145 in the MYO6 3'UTR resulted in a loss of responsiveness to the corresponding miRNA; Our data indicate that miR-143 and miR-145 are involved in the regulation of MYO6 expression and possibly in the development of prostate cancer |
58 |
hsa-miR-145-5p |
NAA15 |
-0.54 |
0.27552 |
0.14 |
0.53335 |
miRNATAP |
-0.11 |
0 |
|
NA |
59 |
hsa-miR-145-5p |
NAA50 |
-0.54 |
0.27552 |
0.33 |
0.22795 |
MirTarget; miRNATAP |
-0.16 |
0 |
|
NA |
60 |
hsa-miR-145-5p |
NDUFA4 |
-0.54 |
0.27552 |
0.1 |
0.74299 |
miRNAWalker2 validate |
-0.11 |
0 |
|
NA |
61 |
hsa-miR-145-5p |
NIPSNAP1 |
-0.54 |
0.27552 |
0.38 |
0.14097 |
miRNAWalker2 validate |
-0.14 |
0 |
|
NA |
62 |
hsa-miR-145-5p |
NRAS |
-0.54 |
0.27552 |
0.46 |
0.05093 |
miRNAWalker2 validate; MirTarget; miRNATAP |
-0.18 |
0 |
26973415 |
miR-145 expression was significantly downregulated in colon cancer tissues with its expression in normal colonic tissues being 4-5-fold higher two sample t test P < 0.05 whereas N-ras expression showed the opposite trend |
63 |
hsa-miR-145-5p |
NRCAM |
-0.54 |
0.27552 |
0.1 |
0.72382 |
MirTarget |
-0.16 |
0.01969 |
|
NA |
64 |
hsa-miR-145-5p |
NSUN4 |
-0.54 |
0.27552 |
0.13 |
0.51843 |
MirTarget |
-0.11 |
0 |
|
NA |
65 |
hsa-miR-145-5p |
NUAK2 |
-0.54 |
0.27552 |
1.06 |
0 |
MirTarget |
-0.23 |
0 |
|
NA |
66 |
hsa-miR-145-5p |
NUDT1 |
-0.54 |
0.27552 |
0.17 |
0.33344 |
miRTarBase |
-0.13 |
2.0E-5 |
21289483 |
MiR 145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1; The mRNA expressions of EGFR and NUDT1 were significantly downregulated after miR-145 transfection in human lung adenocarcinoma cells; Our results demonstrated miR-145 in the negative regulation of EGFR and NUDT1 expressions at both mRNA and protein levels; Upregulation of miR-145 appeared to be an important gene regulation mechanism for the proliferation of lung adenocarcinoma cells and it correlated strongly with the downregulation of EGFR and NUDT1; Our findings provided new insight into the complex regulating pathway comprising of miR-145 EGFR NUDT1 and other unknown factors which function in cell proliferation but not in apoptosis |
67 |
hsa-miR-145-5p |
ONECUT2 |
-0.54 |
0.27552 |
0.73 |
0.00177 |
mirMAP; miRNATAP |
-0.33 |
0 |
|
NA |
68 |
hsa-miR-145-5p |
PIGF |
-0.54 |
0.27552 |
-0.01 |
0.95306 |
miRNAWalker2 validate; MirTarget |
-0.12 |
0 |
|
NA |
69 |
hsa-miR-145-5p |
PLAGL2 |
-0.54 |
0.27552 |
0.64 |
0.00673 |
MirTarget; miRNATAP |
-0.15 |
0 |
|
NA |
70 |
hsa-miR-145-5p |
PTP4A2 |
-0.54 |
0.27552 |
0.38 |
0.15419 |
miRNAWalker2 validate; MirTarget; miRNATAP |
-0.12 |
0 |
|
NA |
71 |
hsa-miR-145-5p |
RAB11FIP4 |
-0.54 |
0.27552 |
0.75 |
0.00176 |
MirTarget |
-0.32 |
0 |
|
NA |
72 |
hsa-miR-145-5p |
RTKN |
-0.54 |
0.27552 |
0.15 |
0.49735 |
miRNAWalker2 validate; MirTarget; miRNATAP |
-0.16 |
0 |
19360360 |
miR 145 inhibits breast cancer cell growth through RTKN; Subsequently RTKN is identified as a potential miR-145 target by bioinformatics; Using reporter constructs we show that the RTKN 3' untranslated region 3'UTR carries the directly binding site of miR-145; Additionally overexpression of miR-145 in MCF-7 reduces RTKN protein expression as well as mRNA level; Taken together we propose that loss of miR-145 may provide a selective growth advantage for MCF-7 by targeting RTKN |
73 |
hsa-miR-145-5p |
SAMD12 |
-0.54 |
0.27552 |
0.7 |
0.00256 |
miRNATAP |
-0.11 |
0.02478 |
|
NA |
74 |
hsa-miR-145-5p |
SCAMP3 |
-0.54 |
0.27552 |
0.06 |
0.8064 |
MirTarget; miRNATAP |
-0.15 |
0 |
|
NA |
75 |
hsa-miR-145-5p |
SEL1L3 |
-0.54 |
0.27552 |
-0.73 |
0.00407 |
miRNATAP |
-0.16 |
1.0E-5 |
|
NA |
76 |
hsa-miR-145-5p |
SHISA9 |
-0.54 |
0.27552 |
0.42 |
0.17623 |
MirTarget |
-0.43 |
0 |
|
NA |
77 |
hsa-miR-145-5p |
SLC19A1 |
-0.54 |
0.27552 |
-0.2 |
0.25408 |
mirMAP |
-0.16 |
0 |
|
NA |
78 |
hsa-miR-145-5p |
SORT1 |
-0.54 |
0.27552 |
-0.06 |
0.84493 |
mirMAP |
-0.11 |
0 |
|
NA |
79 |
hsa-miR-145-5p |
SPATS2 |
-0.54 |
0.27552 |
-0.54 |
0.01372 |
MirTarget |
-0.11 |
0 |
|
NA |
80 |
hsa-miR-145-5p |
STAT1 |
-0.54 |
0.27552 |
1.06 |
0.00069 |
miRNAWalker2 validate; miRTarBase |
-0.22 |
0 |
20098684 |
MicroRNA 145 targets YES and STAT1 in colon cancer cells; Both YES and STAT1 were verified as direct miR-145 targets |
81 |
hsa-miR-145-5p |
SYAP1 |
-0.54 |
0.27552 |
-0.22 |
0.35569 |
mirMAP |
-0.14 |
0 |
|
NA |
82 |
hsa-miR-145-5p |
TARS2 |
-0.54 |
0.27552 |
0.31 |
0.12358 |
MirTarget |
-0.2 |
0 |
|
NA |
83 |
hsa-miR-145-5p |
TFCP2L1 |
-0.54 |
0.27552 |
-0.11 |
0.6529 |
mirMAP |
-0.32 |
0 |
|
NA |
84 |
hsa-miR-145-5p |
TMEM139 |
-0.54 |
0.27552 |
0.49 |
0.02931 |
MirTarget |
-0.19 |
6.0E-5 |
|
NA |
85 |
hsa-miR-145-5p |
TPM3 |
-0.54 |
0.27552 |
0.04 |
0.90658 |
miRNAWalker2 validate |
-0.17 |
0 |
|
NA |
86 |
hsa-miR-145-5p |
TXNDC9 |
-0.54 |
0.27552 |
0.45 |
0.02022 |
MirTarget |
-0.15 |
0 |
|
NA |
87 |
hsa-miR-145-5p |
UNC13A |
-0.54 |
0.27552 |
1.23 |
0 |
mirMAP |
-0.18 |
0.00559 |
|
NA |
88 |
hsa-miR-145-5p |
VAX1 |
-0.54 |
0.27552 |
-0.6 |
0.10712 |
mirMAP |
-0.21 |
0.02161 |
|
NA |
89 |
hsa-miR-145-5p |
VEGFA |
-0.54 |
0.27552 |
0.32 |
0.27688 |
miRNAWalker2 validate; miRTarBase |
-0.16 |
0 |
24781864; 24966896; 22472569 |
Overexpression of miR-145 in thyroid cancer cell lines resulted in: decreased cell proliferation migration invasion VEGF secretion and E-cadherin expression; In vivo miR-145 overexpression decreased tumor growth and metastasis in a xenograft mouse model and VEGF secretion;The ectopic expression of miR-1 and miR-145 in NOZ cells significantly inhibited cell viability and colony formation P<0.01 and reduced gene expression of VEGF-A and AXL;Furthermore the results showed that vascular endothelial growth factor VEGF expression was down-regulated in osteosarcoma cells after miR-145 transfection; On the basis of these results we performed the luciferase assay and verified that miR-145 could down-regulate VEGF at the translational level by partially binding to VEGF 3' untranslated region 3'UTR; One of the mechanisms is the down-regulation of VEGF expression by miR-145 by binding to the 3'UTR of VEGF mRNA specifically |
90 |
hsa-miR-145-5p |
ZBTB33 |
-0.54 |
0.27552 |
0.28 |
0.17068 |
MirTarget |
-0.1 |
0 |
|
NA |
91 |
hsa-miR-145-5p |
ZDHHC9 |
-0.54 |
0.27552 |
-0.32 |
0.17619 |
MirTarget; miRNATAP |
-0.11 |
1.0E-5 |
|
NA |
92 |
hsa-miR-145-5p |
ZNF593 |
-0.54 |
0.27552 |
-0.06 |
0.78738 |
MirTarget |
-0.12 |
2.0E-5 |
|
NA |